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AbsTrACT
background Presentation with advanced glaucoma 
is the major risk factor for lifetime blindness. Effective 
intervention at diagnosis is expected to minimise risk of 
further visual loss in this group of patients.
Aim To compare clinical and cost-effectiveness of 
primary medical management compared with primary 
surgery for people presenting with advanced open-angle 
glaucoma (OAG).
Methods  Design: A prospective, pragmatic multicentre 
randomised controlled trial (RCT).
setting Twenty-seven UK hospital eye services.
Participants Four hundred and forty patients 
presenting with advanced OAG, according to  
the Hodapp-Parish-Anderson classification of visual field 
loss.
Intervention Participants will be randomised to 
medical treatment or augmented trabeculectomy (1:1 
allocation minimised by centre and presence of advanced 
disease in both eyes).
Main outcome measures The primary outcome is 
vision-related quality of life measured by the National 
Eye Institute—Visual Function Questionnaire-25 
at 24 months. Secondary outcomes include generic 
EQ-5D-5L, Health Utility Index-3 and glaucoma-
related health status (Glaucoma Utility Index), patient 
experience, visual field measured by mean deviation 
value, logarithm of the mean angle of resolution visual 
acuity, intraocular pressure, adverse events, standards 
for driving and eligibility for blind certification. 
Incremental cost per quality-adjusted life-year (QALY) 
based on EQ-5D-5L and glaucoma profile instrument 
will be estimated.
results The study will report the comparative 
effectiveness and cost-effectiveness of medical 
treatment against augmented trabeculectomy in 
patients presenting with advanced glaucoma in terms 
of patient-reported health and visual function,  
clinical outcomes and incremental cost per QALY at 
2 years.
Conclusions Treatment of Advanced Glaucoma Study 
will be the first RCT reporting outcomes from the 
perspective of those with advanced glaucoma.
Trial registration number ISRCTN56878850, Pre-
results.
InTroduCTIon
Advanced visual field (VF) loss at glaucoma diag-
nosis is the major risk factor for lifetime blindness.1 
Reducing intraocular pressure (IOP) by medica-
tions, surgery or laser is the only currently avail-
able treatment option for glaucoma.2–9 Glaucoma 
guidelines suggest that primary surgery may be a 
suitable option for presentation with advanced 
glaucoma.10–12
Evidence from a systematic review,2 including 
four randomised controlled trials (RCTs),3 13–15 
comparing primary medical versus surgical treat-
ment for open-angle glaucoma (OAG) suggests that 
treatment failure was more likely when the primary 
treatment was medication (OR 3.90, 95% CI 1.60 
to 9.53; HR 7.27, 95% CI 2.23 to 25.71). Data 
from the largest and most recent of these RCTs 
found no substantial difference in patient-reported 
outcomes between intervention groups at 5 years.16 
However, this study did not include people with 
advanced glaucoma. Subsequent to these studies 
being completed, many more glaucoma medications 
have become available with better efficacy in terms 
of IOP lowering and less side effects.17 Trabeculec-
tomy remains the conventional primary surgery, but 
the technique has evolved18 19 to include the use of 
wide application mitomycin C (MMC),20 releasable 
sutures21 and extensive postoperative manipula-
tion22 to improve outcomes.23
Given that advanced glaucoma is a sight-threat-
ening disease with uncertainty about the best 
primary treatment option, there is a need for a high-
quality study comparing contemporary medications 
with primary trabeculectomy for newly diagnosed 
advanced glaucoma reporting outcomes relevant to 
patients, clinicians and health services.
PATIenTs And MeThods
The Treatment of Advanced Glaucoma Study 
(TAGS) is a pragmatic24 25 multicentre RCT 
comparing primary medical treatment with primary 
augmented trabeculectomy with the primary 
outcome assessment at 2 years post randomisation. 
Participants will be randomised to medical treat-
ment or augmented trabeculectomy (1:1 allocation 
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box Inclusion and exclusion criteria
Inclusion criteria
1. Severe glaucomatous visual field loss (Hodapp classification) 
in one or both eyes at presentation on any of these criteria:
a. Mean deviation <−12.00 dB.
b. >50% of points defective in the pattern deviation 
probability plot at the 5% level (>27 points on 24-2 HVF).
c. >20 points defective at the 1% level.
d. A point in the central 5 degrees has a sensitivity of 0 dB.
e. Points within 5 degrees of fixation<15 dB sensitivity in 
both upper and lower hemifields.
2. Diagnosis of open-angle glaucoma including pigment 
dispersion glaucoma, pseudo-exfoliative glaucoma and 
normal tension glaucoma.
3. Adult≥18 years.
4. Ability to provide informed consent and willingness to 
participate in the trial.
exclusion criteria
1. Visual field defects not meeting advanced visual field loss 
criteria in either eye.
2. Primary angle closure glaucoma and all other secondary 
glaucomas.
3. Inability to undergo incisional surgery due to inability to lie 
flat or unsuitable for anaesthetic.
4. High risk of trabeculectomy failure such as previous 
conjunctival surgery, complicated cataract surgery.
5. Women who are
a. (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) 
of childbearing potential not using a reliable method of 
contraception.
Table 1 Timing of outcome measurements
baseline
Post randomisation (months)
1 3 4 6 12 18 24
Clinical
  Medical history x
  Humphrey visual field mean deviation x x x x
  Esterman Visual Field x x
  LogMAR visual acuity x x x x
  Intraocular pressure x x x x
  Standard clinical examination x x x
Patient experience
  NEI-VFQ-25 x x x x
  EQ-5D-5L* x x x x x x x
  HUI-3* x x x x x x x
  GUI* x x x x x x x
  Patient experience questions x x x x x x x
Health economics
  Healthcare utilisation (including hospital visits) x x x
  Participant cost x x x
  Participant time and travel x
*Additional questionnaire undertaken immediately prior to trabeculectomy surgery; discrete choice experiment at 27 months;
GUI, Glaucoma Utility Index; HUI-3, Health Utility Index; LogMAR, logarithm of the mean angle of resolution; NEI-VFQ25, National Eye Institute Visual Function Questionnaire (25 
items).
minimised by centre and presence of advanced disease in both 
eyes). The trial’s protocol reflects routine care to ensure that the 
results are representative of current clinical practice.
Participants
Adults (≥18 years) presenting with advanced (severe) glaucoma 
in at least one eye will be invited to participate. Advanced disease 
is classified according to the ‘severe’ category of VF loss using 
the Hodapp classification of glaucoma severity26 (see box for a 
full list of eligibility criteria). Two baseline Humphrey VFs (24-2 
SITA Standard) will be performed on all participants prior to 
randomisation to confirm eligibility. If both eyes are eligible, it 
is the participant, not the eye, who is randomised to treatment; 
both eyes receive the same intervention.
Participants will be recruited from an estimated 27 hospitals 
in the UK over a 36-month period. Participants will be followed 
for 2 years from randomisation (see table 1 for the schedule of 
assessments).
study interventions
An individualised target IOP will be set at baseline according to 
the algorithm developed by the Canadian Consensus on target 
IOP setting.27
In the primary medical treatment arm, participants will start 
on one or more medications at their initial visit depending on 
the judgement of the treating clinician and as advised by the 
National Institute for Health and Care Excellence (NICE) glau-
coma guideline,10 with subsequent additional medication based 
on clinician judgement. All currently available licensed drops 
may be used. If drops fail to lower the IOP adequately, oral 
carbonic anhydrase inhibitors may be used. If medical treatment 
fails, patients will be offered glaucoma surgery.
In the primary trabeculectomy group, surgery will be under-
taken within 3 months of randomisation by a surgeon who 
specialises in glaucoma or a glaucoma fellow who has performed 
at least 30 trabeculectomies. Patients’ IOP will be medically 
controlled until glaucoma surgery is undertaken. In trabeculec-
tomy augmented with MMC, a ‘guarded fistula’ is created by 
making a small hole in the eye, covered by a flap of partial thick-
ness sclera.18 28 After glaucoma surgery, medical treatment may 
be introduced if the IOP is above the desired target.
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Table 2 Trial outcomes
outcome Analysis
Primary
objective
Patient-centred:
Vision-specific health profile (NEI-VFQ25) at 
24 months
Intention to treat.
Secondary
objectives
Patient-centred:
Patient-reported health status, HUI-3; EQ-5D-5L 
(5-level), GUI, NEI-VFQ25; patient experience.
Clinical:
Visual field mean deviation at 24 months.
Intraocular pressure; logMAR visual acuity; need 
for cataract surgery; visual standards for driving; 
registered visual impairment; safety.
Economic:
Incremental cost per QALY gained (based on 
responses to the EQ-5D-5L; HUI-3); incremental 
cost per QALY gained (based on responses to 
glaucoma profile instrument (GPI)); incremental 
costs to the NHS, personal social services and 
patients.
Profile over time 
will be analysed by 
repeated measures 
using a linear mixed 
model. Subgroup 
analyses will explore 
potential effect 
modification of gender, 
age, one or both eyes 
affected and extent 
of visual field loss at 
baseline (<–20 dB, 
≥20 dB) on the primary 
outcomes.
GPI, glaucoma profile instrument; GUI, Glaucoma Utility Index; HUI-3, Health Utility 
Index; LogMAR, logarithm of the mean angle of resolution; NEI-VFQ25, National 
Eye Institute Visual Function Questionnaire (25 items); NHS, National Health Service; 
QALY, quality-adjusted life-year.
Where both eyes are eligible and the participant is allocated 
to the surgery arm, a decision as to which eye will undergo 
trabeculectomy first will be made by the clinician and patient 
together. A period of 2–3 months will be allowed between these 
operations.
summary of outcomes
The primary outcome is vision-related quality of life (QoL) 
collected with the National Eye Institute Visual Function Ques-
tionnaire (25 items) (NEI-VFQ25). Secondary outcomes include 
clinical outcomes: mean deviation (MD) on Humphrey VF 
testing, logarithm of the mean angle of resolution (logMAR) 
visual acuity, IOP, complications of treatment, need for cata-
ract surgery; patient-reported outcomes: generic health status 
(EQ-5D-5L and Health Utility Index (HUI-3)), glaucoma health 
status (glaucoma profile instrument (GPI)), patient experi-
ence; and health economic outcomes: quality-adjusted life-year 
(QALYs) and incremental cost per QALY (tables 1 and 2).
The NEI-VFQ25 is a vision-specific patient-reported QoL 
instrument widely used to evaluate visual outcomes in glau-
coma.29–32 Generic EQ-5D-5L,33 HUI-334 and the glaucoma-spe-
cific, GPI35 will be collected to generate utility outcomes. VF 
MD change measures the amount of vision loss due to glaucoma. 
VF damage is the major clinical measure of the functional impact 
of glaucoma, which adversely influences QoL.29 36–38 VFs eligible 
for analysis will have to achieve a predefined reliability criterion 
(false positives<15%). VFs will be assessed by an independent 
VF reading centre, masked to the treatment received by the 
study participant. The independent reading centre will evaluate 
MD change and whether the Esterman Visual Fields achieve 
driving standard levels.
IOP will be measured by Goldmann tonometry in mm Hg. 
The measurement will be undertaken by two observers, the first 
observer making the measurement and the second reading it 
from the measurement dial. Two measurements will be taken and 
a third if there is a discrepancy >3 mm Hg between the first two. 
The mean of these values will be used.
Best-corrected logMAR visual acuity at 4 m will be measured 
on each eye and binocularly. Complications of surgery, need for 
cataract surgery and therapy changes, will be captured from the 
participants’ case records. All clinical outcomes will be recorded 
on a trial-specific case report form (CRF). If a participant is 
eligible to be registered as visually impaired or severely visually 
impaired in the opinion of the consulting clinician, this will be 
recorded in the study CRF at 24 months.
economic outcomes
Costs of treatments (surgery/medications) including time in 
hospital and secondary care use will be based on data collected 
in the trial CRFs. Primary care, personal social service use and 
participant costs will be collected via questionnaires at 4, 12 and 
24 months post randomisation. Responses to the EQ-5D-5L 
(recommended for use by NICE in the UK), HUI-3 (which has 
vision-related questions) and GPI (which should be more sensi-
tive to changes in glaucoma) will be combined with the rele-
vant scoring tariffs35 39 40 to produce QALYs. Glaucoma-specific 
scoring tariffs will be elicited in this study using a discrete choice 
experiment, replicating the method adopted by Burr et al35 with 
a sample of people with advanced glaucoma. Costs and QALYs 
will be combined in a cost–utility analysis both ‘within trial’ and 
modelled over the patient’s lifetime; with the model informed by 
previous models conducted.41–43
sample size
The primary outcome is patient-reported vision-related QoL 
measured by the NEI-VFQ25 at 24 months. A study with 190 
participants in each group will have 90% power at 5% signifi-
cance level to detect a difference in means of 0.33 of an SD; this 
translates to 6 points on the NEI-VFQ25 assuming a common SD 
of 18 points from previous work in patients with advanced glau-
coma.44 Seven points is a likely minimally important difference 
based on our pilot work on NEI-VFQ25 scores in patients with 
glaucoma,45 but there is uncertainty and so we have opted for a 
more conservative six-point difference, which is supported by 
the literature for another chronic eye disease, macular degenera-
tion.46 Assuming a 13.5% dropout due to death and participants 
declining follow-up, we need to randomise 440 participants to 
detect this difference.
For the secondary clinical outcome (VF MD), the study has 
90% power at a 5% level of significance to detect a 1.3 dB 
difference in MD between groups after 2 years. This was derived 
from a subgroup of patients with advanced glaucoma2 47 and is a 
clinically meaningful difference in the context of advanced glau-
coma, given that progressive loss tends to be linear,48 49 with 
small changes over a short period extrapolating to large changes 
over a patient’s lifetime.
recruitment
Patients likely to be eligible for the trial will be identified at the 
initial consultation for glaucoma and provided with a partici-
pant information leaflet. Eligible participants, who agree to take 
part, will sign a consent form before being randomised. Recruit-
ment will be performed by the ophthalmologist and must be 
completed within 3 months of glaucoma diagnosis.
Randomisation will be performed at recruitment centres 
using the remote-automated computer randomisation service 
at the Centre for Healthcare Randomised Trials, either over 
the internet or by telephone. Randomisation will be mini-
mised by centre and whether there is advanced glaucoma in 
both eyes. The unit of randomisation is the participant (not 
the eye).
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Table 3 Expected adverse events
Visual acuity loss of vision (any of the following):
 ► Irreversible loss of 10 ETDRS letters of logarithm of the mean angle of resolution visual acuity
 ► Loss of two or more stages of categorical visual acuity measurement (count fingers, hand motion, light perception, no light perception)
 ► Any loss to no light perception
Intervention 1
Medical treatment*
Intervention 2
Trabeculectomy with mitomycin C
Redness, stinging, itching, transient blurred vision, eyes watering, 
ocular discomfort, allergy, eyelash growth, change in skin colour 
around eye, change in iris colour, shortness of breath, unpleasant 
taste in mouth, dry mouth, fatigue, kidney stones, skin rash, cataract 
formation and retinal detachment*
Discomfort, blurred vision, corneal epithelial defect, conjunctival button-hole, flap dehiscence, intraocular 
pressure too low, transient choroidal effusion, suprachoroidal haemorrhage, hyphema, early bleb leak, 
late bleb leak, shallow anterior chamber (grades 1–3), iris incarceration, persistent uveitis, transient or 
permanent ptosis, macular oedema, malignant glaucoma, corneal decompensation, cataract formation 
and retinal detachment, bleb infection, bleb related endophthalmitis, permanent severe loss of vision 
at time of surgery (<1/500), bleeding in the eye, broad complex tachycardia while under general 
anaesthetic, postoperative dizziness
*In some case, these symptoms may be due to preservatives in the drops—if this is the case, preservative free drops can be used.
These are based on knowledge of adverse events associated with augmented trabeculectomy and the relevant product information documented in the summary of product 
characteristics (SmPC). The latest online version of the appropriate SmPC will be considered in the assessment of an adverse event.
Adverse events/safety reporting
Serious adverse events (SAEs) related to participants’ glau-
coma care or participation in the trial will be reported in 
accordance with the guidance from the UK Health Research 
Authority (http://www. hra. nhs. uk/ research- community/ during- 
your- research- project/ safety- reporting/). Table 3 describes the 
expected adverse events.
All related SAEs will be summarised and reported to the Ethics 
Committee, the funder and the Trial Steering Committee in 
regular progress reports. Any serious, related and unexpected 
events will be expeditiously reported (no later than 15 calendar 
days after the trial team are first aware of the event).50
Procedure
Table 1 displays the timing of the trial’s outcome measurements. 
At baseline, following consent but prior to randomisation, partic-
ipants’ relevant medical history, IOP, Humphrey visual fields and 
best-corrected logMAR visual acuity will be measured. A general 
ophthalmic examination including central corneal thickness will 
also be undertaken. Participants will complete a questionnaire 
including the NEI-VFQ25, EQ-5D-5L, HUI-3, GPI and a ques-
tion asking about the patient’s experience of glaucoma.
Most of the outcomes will be gathered at four time points 
across the 2-year follow-up as illustrated in figure 1 (see table 1 
for details).
statistical analyses
Baseline characteristics, follow-up measurements and safety 
data will be described using the appropriate descriptive 
summary measures. The primary outcome, NEI-VFQ25 score, 
will be analysed using linear regression adjusting for baseline 
NEI-VFQ25 score and other prognostic variables, for example, 
amount of vision loss and IOP at baseline, one or both eyes 
affected by advanced glaucoma. We will also explore the profile 
of NEI-VFQ25 score over time using a linear mixed model to 
analyse data from all time points. All models will include a 
random effect for surgeon. The primary analysis strategy will be 
intention to treat. We will describe the amount and patterns of 
missing data and use appropriate methods,51 if required, to run 
sensitivity analysis to test assumptions.52
There is potential for cross-over to the alternative treatment 
(non-compliance with allocation). In addition to the ‘effec-
tiveness’ estimate from the intention-to-treat analyses, we will 
explore ‘efficacy’ estimates using causal modelling methods suit-
able for complex interventions,53 if required.
Secondary outcomes will be analysed with a similar strategy, 
with models suitable for the outcome (ie, logistic regression for 
the dichotomous outcome ‘need for cataract surgery’ at 2 years). 
Outcomes measured at the eye level will be analysed initially 
using data from the index eye only. For participants with both 
eyes eligible, the eye with the better MD value (less severe VF 
damage) is nominated the index eye for the purposes of the 
statistical analyses.
Sensitivity analysis using data from all eligible eyes will be 
done, including a random effect at the participant level to reflect 
the lack of independence of eyes within participants. All treat-
ment effects will be derived from these models and presented 
with 95% CIs.
Planned subgroup analyses are intended to explore potential 
effect modifications of gender, age, one or both eyes affected 
and extent of VF loss in the index eye at baseline (<–20 dB, 
≥20 dB) on the primary outcomes. Subgroup by treatment inter-
action will be assessed by including interaction terms in the 
models outlined above.
The Data Monitoring Committee will monitor safety and 
other data at 6-monthly intervals during the recruitment phase 
of the trial. Due to the staggered nature of recruitment and the 
primary outcome measurement at 2 years, we do not anticipate 
early termination for benefit. We have planned for one main 
effectiveness analysis at the end of the trial. All statistical anal-
ysis will be detailed in the Statistical Analysis Plan, which will be 
completed before the final analysis is started.
The study adheres to the tenets of the Declaration of 
Helsinki and the principles of Good Clinical Practise (GCP), 
and is in accordance with all applicable regulatory guidance, 
including, but not limited to, the Research Governance Frame-
work. TAGS’ protocol and patient-facing documentation were 
prospectively reviewed and approved by the Derby 1 Research 
Ethics Committee (Ref Number 13/EM/00395). Local NHS 
Research and Development (R&D) approvals were obtained 
prior to commencement of the trial at the participating sites. 
An independent data and safety monitoring committee oversees 
the trial.
Funding
The trial is funded by a grant awarded by the Health Technology 
Assessment (NIHR HTA) programme (project number 12/35/38). 
TAGS is registered on the ISRCTN registry: 56878850.
Nottingham University Hospitals NHS Trust sponsors the trial 
and provides the necessary trial insurance.  o
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Figure 1 Study flow chart with outcome timeline. GPI, glaucoma profile instrument; HUI, Health Utility Index; NEI-VFQ25, National Eye Institute 
Visual Function Questionnaire (25 items); RCT, randomised controlled trial.
dIsCussIon
Major changes in the efficacy, safety and variety of glaucoma 
drops available over the last two decades as well as significant 
modifications to trabeculectomy surgery have improved safety 
and efficacy outcomes.18 23
There is uncertainty regarding the optimal primary treatment 
pathway for people presenting with advanced glaucoma. There 
is a recognition that advanced glaucoma at presentation needs 
to be treated more aggressively.10–12 In the UK, only about 30% 
of UK ophthalmologists follow the NICE guidelines for primary 
surgery.54 Clinicians indicated that robust evidence supporting 
the best primary approach would change their practice.54 The 
TAGS study aims to address this evidence gap.
Patient-reported outcomes are an important component of 
treatment choice and are related to the extent of VF loss.50 55 
TAGS is the first glaucoma surgery RCT with patient-reported 
vision-related QoL as the prespecified primary outcome. As 
both treatments being tested have proven efficacy in treating 
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glaucoma, there may be little measurable difference in clinical 
outcomes. Loss of visual function leads to disability in tasks of 
daily living.56–64 In patients with advanced glaucoma, because 
of their limited visual reserve, further VF loss is likely to result 
in noticeable difference in visual function in all aspects of life 
related to vision.
The participant ‘journey’ through both treatment options 
following diagnosis will be recorded with a vision-specific (NEI-
VFQ25), generic (EQ-5D-5L and HUI-3) and glaucoma-specific 
(GPI) patient-reported questionnaires capturing any QoL differ-
ences between a primary surgery and a primary medication care 
pathway. We will also explore which generic health status ques-
tionnaires, one with a specific visual function domain (HUI-3) 
and one without (EQ-5D-5L), is sensitive to any differences 
between primary treatment options.
Generic QoL assessments have not been previously under-
taken in a medicine versus surgery trial for glaucoma, although 
the Collaborative Initial Glaucoma Treatment Study3 31 reported 
on differences in local eye symptoms and visual activities related 
to interventions.16
Measuring our outcome at 2 years will allow us to track the 
patient journey through the active initial management period 
for their glaucoma and will provide us with meaningful infor-
mation regarding patient-reported outcomes, clinical and safety 
outcomes and economic outcomes of the two treatment options 
tested. However, glaucoma is a slowly progressive condition and 
it may take many years for differences in the outcomes of treat-
ment choices to be revealed.47 65–67 Patients with glaucoma live 
for many years following their diagnosis68–72 and it is therefore 
essential to obtain further information about the effect of treat-
ment options in the medium to long term to better inform our 
patients of lifetime outcomes with different treatment options 
and allow more effective economic modelling. We therefore plan 
to seek further funding to allow further evaluation of this cohort 
at 5 years.
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